0001062993-22-008355.txt : 20220322
0001062993-22-008355.hdr.sgml : 20220322
20220322184341
ACCESSION NUMBER: 0001062993-22-008355
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220318
FILED AS OF DATE: 20220322
DATE AS OF CHANGE: 20220322
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Crespo Jessica
CENTRAL INDEX KEY: 0001918616
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36751
FILM NUMBER: 22761093
MAIL ADDRESS:
STREET 1: C/O OCUGEN, INC.
STREET 2: 263 GREAT VALLEY PARKWAY
CITY: MALVERN
STATE: PA
ZIP: 19355
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Ocugen, Inc.
CENTRAL INDEX KEY: 0001372299
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 263 GREAT VALLEY PARKWAY
CITY: MALVERN
STATE: PA
ZIP: 19355
BUSINESS PHONE: 484-328-4701
MAIL ADDRESS:
STREET 1: 263 GREAT VALLEY PARKWAY
CITY: MALVERN
STATE: PA
ZIP: 19355
FORMER COMPANY:
FORMER CONFORMED NAME: HISTOGENICS CORP
DATE OF NAME CHANGE: 20060810
3
1
form3.xml
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
X0206
3
2022-03-18
0
0001372299
Ocugen, Inc.
OCGN
0001918616
Crespo Jessica
C/O OCUGEN, INC.
263 GREAT VALLEY PARKWAY
MALVERN
PA
19355
0
1
0
0
CAO/SVP, Finance
Common Stock
17500
D
Option (Right to Buy)
1.91
2029-10-23
Common Stock
27500
D
Option (Right to Buy)
0.405
2029-12-20
Common Stock
20000
D
Option (Right to Buy)
0.34
2030-05-05
Common Stock
30000
D
Option (Right to Buy)
1.83
2031-01-01
Common Stock
246000
D
Option (Right to Buy)
11.21
2031-04-28
Common Stock
3440
D
Option (Right to Buy)
4.72
2032-01-03
Common Stock
63292
D
Consists of 17,500 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Ocugen Inc.'s (the "Company's") common stock. The restricted stock units vest annually in equal installments over three years commencing on January 3, 2023, subject to continued employment with the Company on the applicable vesting dates. The restricted stock units will be settled on each applicable vesting date in shares of the Company's common stock.
The option vests annually in equal installments over three years commencing on October 23, 2020, subject to continued service with the Company on the applicable vesting dates. The Reporting Person previously exercised and sold 2,500 of the shares underlying the original option grant.
The option vests annually in equal installments over three years commencing on December 20, 2020, subject to continued service with the Company on the applicable vesting dates.
The option vests annually in equal installments over three years commencing on May 5, 2021, subject to continued service with the Company on the applicable vesting dates.
The option vests annually in equal installments over three years commencing on January 1, 2022, subject to continued service with the Company on the applicable vesting dates.
On April 28, 2021, the Reporting Person was granted a performance-based option to purchase 8,600 shares of the Company's common stock based on the Company's satisfaction of five performance criteria prior to the end of the Company's 2021 and 2022 fiscal years, as applicable (the "Performance-Based Option"). With respect to each performance criteria, 10% of the Performance-Based Option vests on the date of the Compensation Committee's determination that the applicable criteria has been achieved (each, a "Determination Date") and an additional 10% vests upon the first anniversary of the applicable Determination Date, subject to the grantee's continued service with the Company on such date.
On November 16, 2021, the Compensation Committee determined that one of the performance criteria had been achieved, resulting in the Performance-Based Option vesting in part as to 1,720 shares. 860 shares of the Performance-Based Option are immediately vested and exercisable, with the remaining 860 shares vesting on November 16, 2022, subject to the Reporting Person's continued service with the Company.
On December 16, 2021, the Compensation Committee determined that the second performance criteria had been achieved, resulting in the Performance-Based Option vesting in part as to 1,720 shares. 860 shares of the Performance-Based Option are immediately vested and exercisable, with the remaining 860 shares vesting on December 16, 2022, subject to the Reporting Person's continued service with the Company.
The option vests annually in equal installments over three years commencing on January 3, 2023, subject to continued service with the Company on the applicable vesting dates.
/s/ Jessica Crespo
2022-03-22